Stop Diabetes individual level intervention is to create and implement strategies to improve identification and prevention of type 2 diabetes risk and create a prevention model that can have impact on type 2 diabetes incidence on population level.
To achieve this, we set up an online type 2 diabetes risk screening tool and applied marketing strategies in order to encourage citizens to complete the test and participate in the study.
Further, we developed a digital application and a face–to–face group counselling model, and we investigate the effectiveness of these interventions compared to routine care in preventing type 2 diabetes in a randomised controlled trial embedded into the public health care system. Our objective is dissemination and implementation of the best strategies into the Finnish health care and society at large.
Specific aims of the StopDia Individual Level study
The specific aims of the StopDia study (individual level) following the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework are to
- improve the Reach of individuals at increased risk,
- evaluate the Effectiveness and cost-effectiveness of the digital lifestyle intervention and the digital and face-to-face group lifestyle intervention in comparison to routine care in a randomized controlled trial (RCT), and
- evaluate the Adoption and Implementation of the StopDia model by the participants and the health care organizations at society level. Finally, we will address the Maintenance of the lifestyle changes at participant level and that of the program at organisatory level after the RCT.
The StopDia study is carried out in the primary health care system as part of the routine actions of three provinces in Finland, including Northern Savo, Southern Carelia, and Päijät-Häme.
We estimate that one fifth of adults aged 18-70 years living in these areas are at increased risk of T2D. We recruit the participants using the StopDia Digital Screening Tool, including questions from the Finnish Diabetes Risk Score (FINDRISC).
About 3 000 individuals at increased risk of T2D (FINDRISC ≥12 or a history of gestational diabetes, impaired fasting glucose, or impaired glucose tolerance) have participated in the one-year randomized controlled trial. We monitor lifestyle factors using the StopDia Digital Questionnaire and metabolism using laboratory tests performed as part of routine actions in the health care system.